Free Trial

Citigroup Issues Pessimistic Forecast for Candel Therapeutics (NASDAQ:CADL) Stock Price

Candel Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Citigroup lowered its price target on Candel Therapeutics from $26 to $20 but maintained a Buy rating, implying 228% upside from the reported share price of $6.09.
  • Analyst views are mixed: MarketBeat reports a Moderate Buy consensus and an average target of $18.29, while Zacks Research and Wall Street Zen recently downgraded the stock to Strong Sell and Sell, respectively.
  • Candel reported a quarterly loss of $0.28 per share, beating the $0.34 loss analysts expected. The clinical-stage biotech develops viral immunotherapies for cancer.
  • Interested in Candel Therapeutics? Here are five stocks we like better.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) had its price objective reduced by equities research analysts at Citigroup from $26.00 to $20.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Citigroup's price objective would indicate a potential upside of 228.41% from the company's current price.

A number of other analysts have also recently issued reports on the company. Zacks Research cut Candel Therapeutics from a "hold" rating to a "strong sell" rating in a report on Wednesday, October 14th. UBS Group reissued a "buy" rating on shares of Candel Therapeutics in a research note on Monday, August 17th. HC Wainwright cut their price objective on shares of Candel Therapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Friday. Jefferies Financial Group began coverage on shares of Candel Therapeutics in a research note on Thursday, October 22nd. They issued a "buy" rating and a $25.00 price objective on the stock. Finally, Wall Street Zen cut Candel Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $18.29.

Check Out Our Latest Research Report on Candel Therapeutics

Candel Therapeutics Stock Down 1.8%

CADL stock traded down $0.11 during mid-day trading on Monday, hitting $6.09. 1,996,615 shares of the company were exchanged, compared to its average volume of 1,451,537. The firm's 50 day simple moving average is $9.75 and its 200 day simple moving average is $8.39. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $14.00. The firm has a market cap of $466.00 million, a P/E ratio of -4.06 and a beta of -0.27. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.57 and a current ratio of 7.57.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. On average, sell-side analysts predict that Candel Therapeutics will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Candel Therapeutics during the 3rd quarter valued at $41,000. Legal & General Group Plc acquired a new stake in Candel Therapeutics during the second quarter worth about $63,000. Cetera Investment Advisers acquired a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $124,000. Renaissance Technologies LLC purchased a new stake in shares of Candel Therapeutics during the 1st quarter worth about $63,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Candel Therapeutics by 19.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company's stock worth $152,000 after purchasing an additional 2,301 shares during the period. 13.93% of the stock is owned by institutional investors and hedge funds.

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Recommended Stories

Analyst Recommendations for Candel Therapeutics (NASDAQ:CADL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Candel Therapeutics Right Now?

Before you consider Candel Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.

While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines